Patents by Inventor Homayoun Sadeghi
Homayoun Sadeghi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240091313Abstract: The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and/or altered receptor binding profile with respect to unmodified VIP.Type: ApplicationFiled: May 2, 2023Publication date: March 21, 2024Inventors: Homayoun SADEGHI, Suzanne DAGHER, Andrew TURNER
-
Patent number: 10080785Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: October 29, 2007Date of Patent: September 25, 2018Assignee: NOVOZYMES BIOPHARMA DK A/SInventors: David J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Publication number: 20180008677Abstract: The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and/or altered receptor binding profile with respect to unmodified VIP.Type: ApplicationFiled: June 13, 2017Publication date: January 11, 2018Inventors: Homayoun SADEGHI, Suzanne DAGHER, Andrew TURNER
-
Patent number: 9700598Abstract: The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and/or altered receptor binding profile with respect to unmodified VIP.Type: GrantFiled: April 8, 2015Date of Patent: July 11, 2017Assignee: PHASEBIO PHARMACEUTICALS, INC.Inventors: Homayoun Sadeghi, Suzanne Dagher, Andrew Turner
-
Publication number: 20160220642Abstract: The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and/or altered receptor binding profile with respect to unmodified VIP.Type: ApplicationFiled: April 8, 2015Publication date: August 4, 2016Inventors: Homayoun SADEGHI, Suzanne DAGHER, Andrew TURNER
-
Patent number: 9029505Abstract: The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and/or altered receptor binding profile with respect to unmodified VIP.Type: GrantFiled: August 16, 2010Date of Patent: May 12, 2015Assignee: Phasebio Pharmaceuticals, Inc.Inventors: Homayoun Sadeghi, Suzanne Dagher, Andrew Turner
-
Patent number: 8946156Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acid vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: May 4, 2012Date of Patent: February 3, 2015Assignees: Human Genome Sciences, Inc., Novozymes Biopharma DK A/SInventors: David J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Publication number: 20130266553Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: May 4, 2012Publication date: October 10, 2013Inventors: David J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Publication number: 20120252732Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: August 18, 2011Publication date: October 4, 2012Inventors: David J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Publication number: 20120141415Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: October 29, 2007Publication date: June 7, 2012Inventors: David J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Publication number: 20120141449Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: October 29, 2007Publication date: June 7, 2012Inventors: David J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Patent number: 8158579Abstract: The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to reduce body weight.Type: GrantFiled: November 30, 2010Date of Patent: April 17, 2012Assignee: BioRexis Pharmaceutical CorporationInventors: David James Ballance, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Patent number: 8129504Abstract: Pharmaceutical compositions containing modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or increased serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, but does exhibit binding to iron and/or the transferrin receptor. Such fusion proteins may be administered orally.Type: GrantFiled: August 28, 2003Date of Patent: March 6, 2012Assignee: Biorexis Technology, Inc.Inventors: Christopher P. Prior, Homayoun Sadeghi, Andrew Turner
-
Publication number: 20110288001Abstract: The present invention provides biologically active proteins that are activatable by peptidase exposure, such as dipeptidase exposure. The biologically active protein may be a recombinant version of a protein factor that is processed from a native precursor molecule in vivo. Upon administration of the recombinant product to a patient in need, the proteins are converted to the active form in the body by endogenous dipeptidase. The design of such products simplifies the manufacturing process, and may provide for additional therapeutic benefits such as improved pharmacokinetics, half-life, and/or safety profile. The present invention further provides methods of treatment with such compounds, as well as methods of production and/or manufacture.Type: ApplicationFiled: December 18, 2009Publication date: November 24, 2011Inventor: Homayoun Sadeghi
-
Publication number: 20110280830Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: February 4, 2009Publication date: November 17, 2011Inventors: Craig A. Rosen, Homayoun Sadeghi, Christopher P. Prior, Andrew J. Turner
-
Publication number: 20110245178Abstract: The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to reduce body weight.Type: ApplicationFiled: November 30, 2010Publication date: October 6, 2011Applicant: BIOREXIS PHARMACEUTICAL CORPORATIONInventors: David James Ballance, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Publication number: 20110178017Abstract: The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and/or altered receptor binding profile with respect to unmodified VIP.Type: ApplicationFiled: August 16, 2010Publication date: July 21, 2011Applicant: PhaseBio Pharmaceuticals, Inc.Inventors: Homayoun Sadeghi, Suzanne Dagher, Andrew Turner
-
Publication number: 20110092677Abstract: Modified fusion proteins of transferrin and therapeutic proteins or peptides, preferably antibody variable regions, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.Type: ApplicationFiled: September 7, 2010Publication date: April 21, 2011Inventors: Homayoun Sadeghi, Christopher P. Prior, Andrew Turner
-
Publication number: 20110091543Abstract: Pharmaceutical compositions containing modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or increased serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, but does exhibit binding to iron and/or the transferrin receptor. Such fusion proteins may be administered orally.Type: ApplicationFiled: August 28, 2003Publication date: April 21, 2011Applicant: BIOREXIS PHARMACEUTICAL CORPORATIONInventors: Christopher P. Prior, Homayoun Sadeghi, Andrew Turner
-
Patent number: 7867972Abstract: The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to reduce body weight.Type: GrantFiled: July 24, 2007Date of Patent: January 11, 2011Assignee: Pharmacia & Upjohn Company, LLCInventors: David James Ballance, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner